|
1
|
Biermann JS, Adkins DR, Agulnik M, et al:
Bone cancer. J Natl Compr Canc Netw. 11:688–723. 2013.PubMed/NCBI
|
|
2
|
Hogendoorn PC; ESMO/EUROBONET Working
Group. Athanasou N, Bielack S, et al: Bone sarcomas: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 21(Suppl 5): v204–v213. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Londono-Joshi AI, Arend RC, Aristizabal L,
et al: Effect of niclosamide on basal-like breast cancers. Mol
Cancer Ther. 13:800–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ye T, Xiong Y, Yan Y, et al: The
anthelmintic drug niclosamide induces apoptosis, impairs metastasis
and reduces immunosuppressive cells in breast cancer model. PLoS
One. 9:e858872014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sack U, Walther W, Scudiero D, et al:
Novel effect of anti-helminthic Niclosamide on S100A4-mediated
metastatic progression in colon cancer. J Natl Cancer Inst.
103:1018–1036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wieland A, Trageser D, Gogolok S, et al:
Anticancer effects of niclosamide in human glioblastoma. Clin
Cancer Res. 19:4124–4136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jin Y, Lu Z, Ding K, et al: Antineoplastic
mechanisms of niclosamide in acute myelogenous leukemia stem cells:
inactivation of the NF-kappaB pathway and generation of reactive
oxygen species. Cancer Res. 70:2516–2527. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu C, Lou W, Zhu Y, et al: Niclosamide
inhibits androgen receptor variants expression and overcomes
enzalutamide resistance in castration-resistant prostate cancer.
Clin Cancer Res. 20:3198–210. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li R, Hu Z, Sun SY, et al: Niclosamide
overcomes acquired resistance to erlotinib through suppression of
STAT3 in non-small cell lung cancer. Mol Cancer Ther. 12:2200–2212.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
You S, Li R, Park D, et al: Disruption of
STAT3 by niclosamide reverses radioresistance of human lung cancer.
Mol Cancer Ther. 13:606–616. 2014. View Article : Google Scholar :
|
|
11
|
Li R, You S, Hu Z, et al: Inhibition of
STAT3 by niclosamide synergizes with erlotinib against head and
neck cancer. PLoS One. 8:e746702013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yo YT, Lin YW, Wang YC, et al: Growth
inhibition of ovarian tumor-initiating cells by niclosamide. Mol
Cancer Ther. 11:1703–1712. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Arend RC, Londoño-Joshi AI, Samant RS, et
al: Inhibition of Wnt/β-catenin pathway by niclosamide: A
therapeutic target for ovarian cancer. Gynecol Oncol. 34:112–120.
2014. View Article : Google Scholar
|
|
14
|
Chen W, Chen M and Barak LS: Development
of small molecules targeting the Wnt pathway for the treatment of
colon cancer: a high-throughput screening approach. Am J Physiol
Gastrointest Liver Physiol. 299:G293–G300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y, Li PK, Roberts MJ, et al:
Multi-targeted therapy of cancer by niclosamide: A new application
for an old drug. Cancer Lett. 349:8–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pan JX, Ding K and Wang CY: Niclosamide,
an old antihelminthic agent, demonstrates antitumor activity by
blocking multiple signaling pathways of cancer stem cells. Chin J
Cancer. 31:178–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang AM, Ku HH, Liang YC, et al: The
autonomous notch signal pathway is activated by baicalin and
baicalein but is suppressed by niclosamide in K562 cells. J Cell
Biochem. 106:682–692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ren X, Duan L, He Q, et al: Identification
of niclosamide as a new small-molecule inhibitor of the STAT3
signaling pathway. ACS Med Chem Lett. 1:454–459. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reed JC: Proapoptotic multidomain
Bcl-2/Bax-family proteins: mechanisms, physiological roles, and
therapeutic opportunities. Cell Death Differ. 13:1378–1386. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oltvai ZN, Milliman CL and Korsmeyer SJ:
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that
accelerates programmed cell death. Cell. 74:609–619. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Korsmeyer SJ, Shutter JR, Veis DJ, et al:
Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and
cell death. Semin Cancer Biol. 4:327–332. 1993.PubMed/NCBI
|
|
22
|
Porter AG and Janicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cohen GM: Caspases: the executioners of
apoptosis. Biochem J. 326:1–16. 1997.PubMed/NCBI
|
|
24
|
Lu W, Lin C, Roberts MJ, et al:
Niclosamide suppresses cancer cell growth by inducing Wnt
co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin
pathway. PLoS One. 6:e292902011. View Article : Google Scholar
|
|
25
|
Tomizawa M, Shinozaki F, Motoyoshi Y, et
al: Niclosamide suppresses hepatoma cell proliferation via the Wnt
pathway. Onco Targets Ther. 6:1685–1693. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fonseca BD, Diering GH, Bidinosti MA, et
al: Structure-activity analysis of niclosamide reveals potential
role for cytoplasmic pH in control of mammalian target of rapamycin
complex 1 (mTORC1) signaling. J Biol Chem. 287:17530–17545. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Balgi AD, Fonseca BD, Donohue E, et al:
Screen for chemical modulators of autophagy reveals novel
therapeutic inhibitors of mTORC1 signaling. PLoS One. 4:e71242009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee SL, Son AR, Ahn J, et al: Niclosamide
enhances ROS-mediated cell death through c-Jun activation. Biomed
Pharmacother. 68:619–624. 2014. View Article : Google Scholar : PubMed/NCBI
|
